Global Anti-Viral Therapies Market Forecast to 2027 – COVID-19 Impact and Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anti-Viral Therapies Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type; Mechanism of Action; Application and Geography” report has been added to ResearchAndMarkets.com’s offering.

According to this report the market is expected to reach US$ 76,282.63 million by 2027 from US$ 40,589.79 million in 2019; it is estimated to grow at a CAGR of 8.3% from 2020 to 2027. The report highlights trends prevailing in the global anti-viral therapies market and the drivers and restraints pertaining to the market growth.

Based on type, the global anti-viral therapies market is segmented into generic drugs and branded drugs. The generic drugs segment is estimated to register a higher CAGR in the market during 2020-2027. Rising demand for low-cost drugs, growing number of FDA-approved generic drugs, rising adoption in emerging nations, and patent expiry of various branded products are the factors boosting the market for the generic drugs segment.

The global anti-viral therapies market growth is mainly attributed to factors such as increasing R&D expenditure in pharmaceutical companies and rising government support for research activities and clinical trials. However, high drug development cost hinders the growth of the market.

AbbVie Inc.; Abbott; Astrazeneca; F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc.; Merck & Co. (Read more…), Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc; and Aurobindo Pharma are among the leading companies operating in the anti-viral therapies market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the anti-viral therapies market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global anti-viral therapies market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

• Increasing R&D Expenditures in Pharmaceutical Companies
• Rising Government Support for Research Activities and Clinical Trials

Restraints

• High Cost of Drug Development

Opportunities

• Emerging Markets

Future Trends

• Growing Emphasis on Launching Anti-Viral Agents

Companies Mentioned

• AbbVie Inc.
• Abbott
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Merck and Co., Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Aurobindo Pharma
• AstraZeneca

For more information about this report visit https://www.researchandmarkets.com/r/pe1uwf.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900